Intramammary antimicrobial sales in Ireland: a 2020 descriptive update.

Intramammary (IM) antimicrobial sales data are currently the only feasible means to gain broad insights into on-farm usage of antimicrobials (AMs) relevant to mastitis control within the Irish dairy industry. The aim of this study was to update earlier work describing sales data of intramammary antimicrobial usage in the Irish dairy industry in 2020. Previously reported data from 2013 to 2019 is included for reference and 2020 sales data is reported using similar methodology to previously published work in this area. Data on IM AMs sold in Ireland during 2013-2020 were obtained from two sources, believed to represent 99% of all sales of IM AMs in Ireland, and analyses were undertaken to evaluate patterns in IM AM sales. We report an increase in overall sales of both lactating cow (LC) and dry cow (DC) IM AMs. We observed a large increase in the use of DC IM AMs, from 0.95 to 1.13 defined course dose (DCDvet) per cow per year in 2019 and 2020 respectively, as well as evidence of ongoing usage of highest priority critically important AMs, as defined by the World Health Organization. There was also a slight increase in LC use of IM AMs, from 0.43 to 0.44 defined course dose (DCDvet) per cow per year. We believe that our results provide an accurate reflection of IM sales in Ireland in 2020. In common with any study of this type, caution is needed when interpreting national IM AM sales data, noting the potential discrepancies between AM sales and on-farm usage. Nonetheless, the sales pattern described here, most importantly the increased use of DC products and ongoing and increasing use of HP CIA products in both DC and LC therapy raise significant concerns for the Irish dairy industry. This study provides an evidence base to inform current policy discussions, particularly in the context of the new Veterinary Medicines Regulation (Regulation (EU) 2019/6), which comes into force on 28 January 2022.